• In the first quarter of 2026, Stoke Therapeutics, Inc. reported sales of US$6.23 million and a net loss of US$50 million, reversing from much higher revenue and a net profit a year earlier.
• This sharp swing from earnings per share of about US$1.90–US$1.95 to a basic loss of US$0.79 highlights how rapidly the company’s financial profile can shift as it advances its RNA medicines pipeline.
• We’ll now examine how this abrupt move from profit to loss in the latest quarter reshapes Stoke Therapeutics’ existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 43 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics today, you have to believe that its antisense RNA platform, led by zorevunersen for Dravet syndrome, can eventually translate clinical progress into sustainable revenue despite near term volatility. The Q1 2026 swing to a US$50.0 million net loss on US$6.23 million in sales is stark, but does not by itself alter the central near term catalyst, which remains the EMPEROR Phase III program and related regulatory milestones, or the biggest current risk, which is trial or approval setbacks.

Among recent announcements, the January 2026 update on EMPEROR enrollment and the planned rolling NDA submission in 2027 feels most linked to this earnings reset. The step up in spending implied by the Q1 loss and prior 2025 results looks closely tied to advancing EMPEROR and preparing for potential commercialization, reinforcing how dependent the story is on successful late stage data and regulatory progress rather than on current collaboration revenue.

Yet while the long term opportunity is compelling, investors should also be aware that...

Stoke Therapeutics' narrative projects $81.1 million revenue and $13.2 million earnings by 2028. This implies revenues will decrease by 26.7% per year and an earnings decrease of $27.4 million from $40.6 million today.

Uncover how Stoke Therapeutics' forecasts yield a $34.25 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already assuming revenue could fall about 50.0% a year and still only reach around US$23.1 million by 2029, so this sharp Q1 loss could push that more cautious view even further, especially if you worry about ongoing EMPEROR trial costs and the timing of any zorevunersen launch.

Explore 5 other fair value estimates on Stoke Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.